Xi Lawrence Wu, BSc

Astellas Pharma Global Development
Northbrook, Illinois, United States

Disclosure information not submitted.

Presentation(s):

• MON-167 - Central Nervous System Safety of Fezolinetant from Pooled Analysis of 52-Week, Phase 3 Studies (SKYLIGHT 1, 2, and 4)

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• ORF38-03 - Central Nervous System Safety of Fezolinetant from Pooled Analysis of 52-Week, Phase 3 Studies (SKYLIGHT 1, 2, and 4)

  Monday, June 15, 2026
  9:40 AM - 9:45 AM CT